Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer

Trends in Biochemical Sciences

Volumn 38, Issue 12, 2013, Pages 612-620

  Zhang, Long ^a,b   Zhou, Fangfang ^b   ten Dijke, Peter ^b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

AKT; Mammalian target of rapamycin complex; Phosphatase and tensin homolog deleted on chromosome 10; Phosphoinositide 3 kinase; SMA and MAD related protein (SMAD) transforming growth factor

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GLYCOGEN SYNTHASE KINASE 3BETA; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAS PROTEIN; S6 KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRASTUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNINDEXED DRUG; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL SURVIVAL; CIRCULATING TUMOR CELL; COLORECTAL CANCER; CYTOSTASIS; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; METASTASIS POTENTIAL; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

AKT; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX; PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME 10; PHOSPHOINOSITIDE 3-KINASE; SMA- AND MAD-RELATED PROTEIN (SMAD) TRANSFORMING GROWTH FACTOR-Β;

DISEASE PROGRESSION; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 84888132688     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2013.10.001     Document Type: Review

References (75)

1. Massagué J. TGF-β signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13:616-630.
2. Katsuno Y., et al. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr. Opin. Oncol. 2013, 25:76-84.
3. Heldin C.H., et al. Regulation of EMT by TGFβ in cancer. FEBS Lett. 2012, 586:1959-1970.
4. Siegel P.M., Massagué J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer 2003, 3:807-821.
5. Sundqvist A., et al. Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. Breast Cancer Res. 2012, 14:204.
6. Mu Y., et al. Non-Smad signaling pathways. Cell Tissue Res. 2012, 347:11-20.
7. Zhang Y.E. Non-Smad pathways in TGF-β signaling. Cell Res. 2009, 19:128-139.
8. Moustakas A., Heldin C.H. Non-Smad TGF-β signals. J. Cell Sci. 2005, 118:3573-3584.
9. Lamouille S., Derynck R. Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J. Cell Biol. 2007, 178:437-451.
10. Yi J.Y., et al. Type I transforming growth factor β receptor binds to and activates phosphatidylinositol 3-kinase. J. Biol. Chem. 2005, 280:10870-10876.
11. Xia H., et al. MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013, 58:629-641.
12. Kato M., et al. TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat. Cell Biol. 2009, 11:881-889.
13. Dey N., et al. TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS ONE 2012, 7:e42316.
14. Sorrentino A., et al. The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 2008, 10:1199-1207.
15. Yamashita M., et al. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β. Mol. Cell 2008, 31:918-924.
16. Yang W.L., et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009, 325:1134-1138.
17. Restuccia D.F., Hemmings B.A. Cell signaling. Blocking activity. Science 2009, 325:1083-1084.
18. Valderrama-Carvajal H., et al. Activin/TGF-β induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat. Cell Biol. 2002, 4:963-969.
19. Massagué J., et al. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309.
20. Massague J. TGFβ in Cancer. Cell 2008, 134:215-230.
21. Peng Z., et al. Dichotomy effects of Akt signaling in breast cancer. Mol. Cancer 2012, 11:61.
22. Conery A.R., et al. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β induced apoptosis. Nat. Cell Biol. 2004, 6:366-372.
23. Remy I., et al. PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3. Nat. Cell Biol. 2004, 6:358-365.
24. Seoane J., et al. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004, 117:211-223.
25. Tzivion G., et al. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim. Biophys. Acta 2011, 1813:1938-1945.
26. Ding Z., et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
27. Qin J., et al. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature 2013, 493:236-240.
28. Thakur N., et al. TGF-β uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells. Future Oncol. 2009, 5:1-3.
29. Moustakas A., Heldin C.H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007, 98:1512-1520.
30. Xu J., et al. TGF-β-induced epithelial to mesenchymal transition. Cell Res. 2009, 19:156-172.
31. Huber M.A., et al. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
32. Miyazono K. Transforming growth factor-β signaling in epithelial-mesenchymal transition and progression of cancer. Proc. Jpn. Acad. Ser. B: Phys. Biol. Sci. 2009, 85:314-323.
33. Naber H.P., et al. Snail and Slug, key regulators of TGF-β-induced EMT, are sufficient for the induction of single-cell invasion. Biochem. Biophys. Res. Commun. 2012, 435:58-63.
34. Kang Y., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
35. Deckers M., et al. The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006, 66:2202-2209.
36. Kang Y., et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:13909-13914.
37. Petersen M., et al. Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene 2010, 29:1351-1361.
38. Padua D., et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77.
39. Leight J.L., et al. Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition. Mol. Biol. Cell 2012, 23:781-791.
40. Barrallo-Gimeno A., Nieto M.A. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005, 132:3151-3161.
41. Zhou B.P., et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 2004, 6:931-940.
42. Julien S., et al. Activation of NF-κB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007, 26:7445-7456.
43. Wu Y., et al. Stabilization of Snail by NF-κB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15:416-428.
44. Xue G., et al. Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes. Cancer Discov. 2012, 2:248-259.
45. Bakin A.V., et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 2000, 275:36803-36810.
46. Itoh F., et al. The FYVE domain in Smad anchor for receptor activation (SARA) is sufficient for localization of SARA in early endosomes and regulates TGF-β/Smad signalling. Genes Cells 2002, 7:321-331.
47. Zhang L., et al. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat. Cell Biol. 2012, 14:717-726.
48. Lim J.H., et al. CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat. Commun. 2012, 3:771.
49. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
50. Xue G., Hemmings B.A. PKB/Akt-dependent regulation of cell motility. J. Natl. Cancer Inst. 2013, 105:393-404.
51. Liu P., et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
52. Akhurst R.J., Hata A. Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 2012, 11:790-811.
53. Bedi A., et al. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol. Cancer Ther. 2012, 11:2429-2439.
54. Deharvengt S., et al. Concomitant targeting of EGF receptor, TGF-β and SRC points to a novel therapeutic approach in pancreatic cancer. PLoS ONE 2012, 7:e39684.
55. Wang S.E., et al. Transforming growth factor β engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell. Biol. 2008, 28:5605-5620.
56. Wang S.E., et al. Transforming growth factor β induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res. 2009, 69:475-482.
57. Yu M., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339:580-584.
58. Huang S., et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 2012, 151:937-950.
59. Leary R.J., et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2010, 2:20ra14.
60. Ji H., et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics 2013, 13:1672-1686.
61. Sato T., et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011, 141:1762-1772.
62. Holliday D.L., et al. The practicalities of using tissue slices as preclinical organotypic breast cancer models. J. Clin. Pathol. 2013, 66:253-255.
63. Singh A.M., et al. Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 2012, 10:312-326.
64. Luo S., et al. TGF-β and insulin signaling regulate reproductive aging via oocyte and germline quality maintenance. Cell 2010, 143:299-312.
65. Glass D.J. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. 2010, 346:267-278.
66. Carnero A., et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 2008, 8:187-198.
67. Cheng G.Z., et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 2008, 8:2-6.
68. Assinder S.J., et al. The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem. J. 2009, 417:411-421.
69. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4240-4245.
70. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 2004, 22:2954-2963.
71. Franke T.F., Cantley L.C. Apoptosis. A bad kinase makes good. Nature 1997, 390:116-117.
72. Cross D.A., et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
73. Liu C., et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108:837-847.
74. Diehl J.A., et al. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12:3499-3511.
75. Sengupta S., et al. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 2010, 40:310-322.